Danuglipron
Danuglipron is a small-molecule GLP-1 agonist, formerly under development by Pfizer that, in an oral formulation, was under investigation as a therapy for diabetes mellitus. Initial results from a randomized controlled trial indicated that it reduced weight and improved diabetic control. The most commonly reported adverse events were nausea, diarrhea, and vomiting. However, in April 2025, Pfizer announced it would abandon further development of Danuglipron due to unpredictable liver toxicity. See also * Lotiglipron Lotiglipron is a non-peptide glucagon-like peptide-1 receptor agonist which was under development by Pfizer as a weight loss drug. However, it was withdrawn from development in June 2023, after early stage clinical trial Clinical trials are p ... * Orforglipron References GLP-1 receptor agonists Experimental diabetes drugs Nitriles Fluoroarenes Disubstituted pyridines Ethers Piperidines Oxetanes Benzimidazoles Carboxylic acids Abandoned drugs ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]